thromboxane-a2 and Migraine-Disorders

PGE2 and TXA2 levels and their modulation by nicardipine, a calcium blocking agent, have been studied in patients suffering from migraine. The levels of both metabolites were determined in saliva obtained during the migraine attacks, during the intervals between attacks, and after 2 months of treatment with nicardipine (20 mg every 8 h.) or placebo. The therapeutic response was evaluated on the basis of the number of migraine attacks. The results show a significant increase in the levels of both eicosanoids during the migraine attacks. In contrast to the placebo group, the number of migraine attacks and the levels of both arachidonic acid metabolites are markedly lower in the nicardipine group. Our results suggest calcium entry into the cytosol as an explanation for the increase in PGE2 and TXA2. Nicardipine interferes with calcium mobilization, thereby inhibiting arachidonic acid metabolite synthesis.

Topics: Adolescent; Adult; Calcium Channel Blockers; Dinoprostone; Female; Humans; Male; Middle Aged; Migraine Disorders; Nicardipine; Saliva; Thromboxane A2

The levels of Prostacyclin (PGI2) and Thromboxane A2 (TXA2) were assayed simultaneously (RIA) in the plasma and saliva of 9 patients suffering from classical migraine attacks. The assays were done during an attack-free period. In relation to the control group we observed a significant decrease in the plasma levels of PGI2 together with a sharp increase in TXA2 in saliva. When the patients were treated with nicardipine, a calcium antagonist, the TXA2 increase in saliva did not occur. These results suggest both a systemic and local effect in the classical migraine attacks. We explain and discuss our results by referring to the PGI2: TXA2 equilibrium system. Nicardipine action might be related to its ability to reduce the calcium entry into the cell induced by thromboxane.

Topics: Adolescent; Adult; Dinoprostone; Female; Humans; Male; Migraine Disorders; Nicardipine; Saliva; Thromboxane A2

Topics: Capillary Permeability; Dinoprostone; Epoprostenol; Humans; Inflammation; Migraine Disorders; Pain; Prostaglandins; Prostaglandins E; Thromboxane A2; Vasoconstriction; Vasodilation

Topics: Adolescent; Adult; Age Factors; Blood Platelets; Child; Child, Preschool; Humans; Middle Aged; Migraine Disorders; Thromboxane A2; Thromboxane B2; Thromboxanes